Skip to content

Effect of selenium therapy on primary autoimmune hypothyroidism: a randomized clinical trial

Effect of selenium therapy on primary autoimmune hypothyroidism: a randomized clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201211239014N13
Enrollment
40
Registered
2012-12-01
Start date
2012-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary autoimmune hypothyroidism. Autoimmune thyroiditis

Interventions

Intervention 1: 20 patients with primary autoimmune hypothyroidism will receive levothyroxine plus selenium tablet 200 microgram once a day for three months. Intervention 2: 20 patients with primary a
Treatment - Drugs
20 patients with primary autoimmune hypothyroidism will receive levothyroxine plus selenium tablet 200 microgram once a day for three months
20 patients with primary autoimmune hypothyroidism will receive levothyroxine only for three months

Sponsors

Vice chancellor for Research the Technology, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) age of 18 to 75 years; (b) having primary autoimmune hypothyroidisms; (c) having anti-TPO >200 U/ml Exclusion criteria: (a) history of Thyroid surgery; (b) history of thyroid cancer; (c) hypothyroidism resulted from hyperthyroidism; (d) history of auto-immune disease and known rheumatologic diseases; (e) pregnancy; (f) renal failure; (g) subclinical hypothyroidism; (h) history of using radioactive iodine, anti thyroid medication, cytotoxic; immunosuppressive, glucocorticoid, amiodaron, lithium, interferon, and chemotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Measurement of anti-TPO titer. Timepoint: ?After three months. Method of measurement: Through electrochemiluminescence using diasorin set and liaison kit.

Secondary

MeasureTime frame
TSH. Timepoint: 3 months post intervention. Method of measurement: Laboratory.;T3. Timepoint: 3 months post intervention. Method of measurement: Laboratory.;T4. Timepoint: 3 months post intervention. Method of measurement: Laboratory.;Abdominal pain. Timepoint: 3 months post intervention. Method of measurement: With question.;Hair loss. Timepoint: 3 months post intervention. Method of measurement: With question.;Dizziness. Timepoint: 3 months post intervention. Method of measurement: With question.;Sensation of garlic smell. Timepoint: 3 months post intervention. Method of measurement: With question.;Tremor. Timepoint: 3 months post intervention. Method of measurement: With question.;Sweating. Timepoint: 3 months post intervention. Method of measurement: With question.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Jalal Poorolajal

Research Center for Health Sciences and Department of Epidemiology & Biostatistics

poorolajal@umsha.ac.ir+98 83 80090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026